Wave Life Sciences Ltd. (NASDAQ: WVE) is a Healthcare company (Biotechnology) with a market capitalization of $676M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Wave Life Sciences Ltd. had a Maz Rating of 1.95 out of 5 (D, Sell), ranked against the other companies in its sector. Its strongest factor then was Financial Health (4.48), above most of its sector; its weakest was Growth (1.99), below most of its sector. The other factors: Valuation 2.49 (more expensive than most of its sector); Profitability 2.26 (below most of its sector); Momentum 2.12 (below most of its sector). The current rating is for members: log in to see it.
At $3.42, Wave Life Sciences Ltd. trades at 9.7x sales and 1.8x book value. Over the last twelve months it generated about $70M of revenue and a net loss of $208M. It runs a gross margin of 96.8%, an operating margin of -320.9% and a net margin of -296.9%. It shows return on equity of -44.5%, return on invested capital of -49.7% and a free cash flow yield of -29.4%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 8.38. Over the past 52 weeks the share price ranged from $3.04 to $21.73, with a beta of -1.44.
Wave Life Sciences Ltd. does not currently pay a dividend.
25 Wall Street analyst ratings cover the stock: 1 Strong Buy, 22 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.